Incorporation of pazopanib in maintenance therapy of ovarian cancer.

@article{Bois2014IncorporationOP,
  title={Incorporation of pazopanib in maintenance therapy of ovarian cancer.},
  author={Andreas du Bois and Anne Floquet and Jae Weon Kim and Joern Rau and Josep Mar{\'i}a Del Campo and Michael Friedlander and Sandro Pignata and Keiichi Fujiwara and Ignace Vergote and Nicoletta Colombo and Mansoor Mirza and Bradley J. Monk and Rainer Kimmig and Isabelle Laure Ray-Coquard and Rongyu Zang and Iv{\'a}n D{\'i}az-Padilla and Klaus Heinrich Baumann and Marie-Ange Mouret-Reynier and Jae-Hoon Kim and Christian Kurzeder and Anne Lesoin and Paul A. Vasey and Christian Marth and Ulrich Canzler and Giovanni Scambia and Muneaki Shimada and Paula Calvert and {\'E}ric Pujade-Lauraine and B Kim and Thomas J. Herzog and Ionel Mitrica and Carmen Schade-Brittinger and Qiong Wang and Rocco J Crescenzo and Philipp Harter},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 30},
  pages={3374-82}
}
PURPOSE Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR) -α/-β, and c-Kit. Preclinical and clinical studies support VEGFR and PDGFR as targets for advanced ovarian cancer treatment. This study evaluated the role of pazopanib maintenance therapy in patients with ovarian cancer whose disease did not progress during first-line chemotherapy. PATIENTS AND METHODS Nine hundred forty patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 77 extracted citations

New perspectives on targeted therapy in ovarian cancer

International journal of women's health • 2015
View 4 Excerpts
Highly Influenced

Pazopanib in ovarian cancer.

Expert review of anticancer therapy • 2015
View 6 Excerpts
Highly Influenced

Ovarian cancer standard of care: are there real alternatives?

Chinese journal of cancer • 2015
View 3 Excerpts
Highly Influenced

Angiogenesis Inhibitors for the Treatment of Ovarian Cancer

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society • 2018

References

Publications referenced by this paper.
Showing 1-10 of 25 references

A phase 3 trial of bevacizumab in ovarian cancer.

The New England journal of medicine • 2011
View 2 Excerpts

First-line therapy in ovarian cancer trials.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society • 2011
View 1 Excerpt

Maintenance chemotherapy for ovarian cancer.

The Cochrane database of systematic reviews • 2010

Similar Papers

Loading similar papers…